{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T09:53:22Z","timestamp":1787478802223,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.critrevonc.2024.104420","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:03:50Z","timestamp":1718813030000},"page":"104420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1078-157X","authenticated-orcid":false,"given":"Rachel","family":"Daher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ruplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cigliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2024.104420_bib1","doi-asserted-by":"crossref","first-page":"35-38","DOI":"10.3315\/jdcr.2016.1226","article-title":"Enzalutamide induced acute generalized exanthematous pustulosis","volume":"10","author":"Alberto","year":"2016","journal-title":"J. Dermatol. Case Rep."},{"issue":"5Part A","key":"10.1016\/j.critrevonc.2024.104420_bib2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ijwd.2021.10.005","article-title":"Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management","volume":"7","author":"Apalla","year":"2021","journal-title":"Int J. Women\u2019s. Dermatol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2024.104420_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.5048","article-title":"ARCHES: efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104420_bib4","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104420_bib5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/fon-2018-0546","article-title":"Apalutamide and its use in the treatment of prostate cancer","volume":"15","author":"Borno","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.critrevonc.2024.104420_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104420_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104420_bib9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104420_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104420_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ced\/llad070","article-title":"Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review","author":"Das","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.736975","article-title":"Stevens-Johnson Syndrome caused by enzalutamide: a case report and literature review","volume":"11","author":"Deng","year":"2021","journal-title":"Front. Oncol."},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2024.104420_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.71","article-title":"Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide","volume":"41","author":"Deol","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104420_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jdcr.2020.04.013","article-title":"Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib","volume":"6","author":"Deutsch","year":"2020","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.critrevonc.2024.104420_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jdcr.2022.01.005","article-title":"Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma","volume":"21","author":"Enescu","year":"2022","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.critrevonc.2024.104420_bib16","unstructured":"Erdafitinib. PubMed. Published 2012. Accessed April 18, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574354\/."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104420_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2024.104420_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1196793","article-title":"Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"14","author":"Feng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113258","article-title":"Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial","volume":"192","author":"Fizazi","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104420_bib20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/TCRM.S158753","article-title":"Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook","volume":"14","author":"Gopalakrishnan","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104420_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2009","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2024.104420_bib23","doi-asserted-by":"crossref","unstructured":"Grivas P., Pouessel D., Park C.H., et al. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. 2023;41(6_suppl):518-518. doi:https:\/\/doi.org\/10.1200\/jco.2023.41.6_suppl.518.","DOI":"10.1200\/JCO.2023.41.6_suppl.518"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104420_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02612-5","article-title":"Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors","volume":"18","author":"Gulati","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2024.104420_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1006101","article-title":"Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104420_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000277656","article-title":"Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among german oncologists","volume":"33","author":"Hassel","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.critrevonc.2024.104420_bib27","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5, Part A","key":"10.1016\/j.critrevonc.2024.104420_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijwd.2021.09.009","article-title":"Cutaneous toxicities from targeted therapies used in oncology: literature review of clinical presentation and management","volume":"7","author":"Huynh Dagher","year":"2021","journal-title":"Int. J. Women\u2019S. Dermatol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104420_bib29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/jjco\/hys103","article-title":"Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma","volume":"42","author":"Ikeda","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104420_bib30","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/cncr.34907","article-title":"Top advances of the year: genitourinary cancer","volume":"129","author":"Jackson-Spence","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104420_bib31","unstructured":"Journal of Prescribing Practice - Enzalutamide in the treatment of metastatic castrate-sensitive prostate cancer. Journal of Prescribing Practice. Accessed September 28, 2023. https:\/\/www.prescribingpractice.com\/content\/pharmacology\/enzalutamide-in-the-treatment-of-metastatic-castrate-sensitive-prostate-cancer\/."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104420_bib32","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.21873\/anticanres.15682","article-title":"Low body weight as a risk factor for apalutamide-related cutaneous adverse events","volume":"42","author":"Katsuta","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2024.104420_bib33","article-title":"Diffuse hyperpigmented lichenoid drug eruption secondary to Enzalutamide","volume":"5","author":"Khan","year":"2022","journal-title":"Curr. Probl. Cancer.: Case Rep."},{"key":"10.1016\/j.critrevonc.2024.104420_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/cup.14383","article-title":"Concomitant nivolumab associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma","author":"Khazaeli","year":"2023","journal-title":"J. Cutan. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104420_bib35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/ph14111077","article-title":"A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine","volume":"14","author":"Kloypan","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104420_bib36","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104420_bib37","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"S1","key":"10.1016\/j.critrevonc.2024.104420_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib39","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","author":"Lacouture","year":"2020","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104420_bib40","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/cancers14184369","article-title":"Management of immune-related adverse events from immune-checkpoint inhibitors in advanced or metastatic renal cell carcinoma","volume":"14","author":"Leucht","year":"2022","journal-title":"Cancers"},{"issue":"suppl 17","key":"10.1016\/j.critrevonc.2024.104420_bib41","doi-asserted-by":"crossref","first-page":"LBA4619","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR study: results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"suppl 17","key":"10.1016\/j.critrevonc.2024.104420_bib42","doi-asserted-by":"crossref","first-page":"LBA4619","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR study: results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103091","article-title":"Prevention and treatment of FGFR inhibitor-associated toxicities","volume":"155","author":"Mahipal","year":"2020","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104420_bib44","article-title":"Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab","volume":"16","author":"McCormick","year":"2023","journal-title":"Case Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104420_bib45","doi-asserted-by":"crossref","DOI":"10.21037\/apm.2019.08.05","article-title":"Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment","volume":"9","author":"McFarlane","year":"2020","journal-title":"Ann. Palliat. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104420_bib46","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3390\/cancers15072084","article-title":"Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma","volume":"15","author":"Nikolaou","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104420_bib47","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell P.H., Milowsky M.I., Petrylak D.P., et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Published online June 27, 2023. doi:https:\/\/doi.org\/10.1200\/jco.22.02887.","DOI":"10.1200\/JCO.22.02887"},{"key":"10.1016\/j.critrevonc.2024.104420_bib48","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.40031","article-title":"Immune checkpoint inhibitors as a treatment option for bladder cancer: current evidence","author":"Okobi","year":"2023","journal-title":"Cureus"},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104420_bib49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt-2019-0027","article-title":"Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma","volume":"11","author":"Palla","year":"2019","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104420_bib50","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/JU.0000000000002425","article-title":"Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide","volume":"207","author":"Pan","year":"2022","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis","volume":"10","author":"Park","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib52","doi-asserted-by":"crossref","unstructured":"Petrylak D.P., Tagawa S.T., Jain R., et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. 2023;41(6_suppl):520-520. doi:https:\/\/doi.org\/10.1200\/jco.2023.41.6_suppl.520.","DOI":"10.1200\/JCO.2023.41.6_suppl.520"},{"key":"10.1016\/j.critrevonc.2024.104420_bib53","article-title":"LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104420_bib54","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1026978","article-title":"The value of the multidisciplinary team in metastatic renal cell carcinoma: paving the way for precision medicine in toxicities management","volume":"12","author":"Roberto","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104420_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2024.104420_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.441","article-title":"Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.12.019","article-title":"Management of fibroblast growth factor inhibitor treatment\u2013emergent adverse events of interest in patients with locally advanced or metastatic urothelial carcinoma","volume":"50","author":"Siefker-Radtke","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.critrevonc.2024.104420_bib59","doi-asserted-by":"crossref","unstructured":"Tagawa S.T., Arjun Vasant Balar, Petrylak D.P., et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). 2023;41(6_suppl):526-526. doi:https:\/\/doi.org\/10.1200\/jco.2023.41.6_suppl.526.","DOI":"10.1200\/JCO.2023.41.6_suppl.526"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104420_bib60","article-title":"Skin rash following administration of apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621591","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin\u2013related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.critrevonc.2024.104420_bib63","article-title":"Adverse effects and toxicity of immune checkpoint inhibitors for patients with urothelial carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib64","unstructured":"World Cancer Research Fund International. Worldwide cancer data | World Cancer Research Fund International. WCRF International. Published 2020. https:\/\/www.wcrf.org\/cancer-trends\/worldwide-cancer-data\/."},{"key":"10.1016\/j.critrevonc.2024.104420_bib65","article-title":"Cutaneous side effects of inhibition of VEGF signal transduction","author":"Wozel","year":"2009","journal-title":"J. der Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.critrevonc.2024.104420_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with enfortumab vedotin: a real-word study leveraging U.S. Food and Drug Administration Adverse Event Reporting System","volume":"11","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104420_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104420_bib68","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0780-z","article-title":"Emerging therapeutic agents for genitourinary cancers","volume":"12","author":"Zarrabi","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282400163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282400163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T02:14:17Z","timestamp":1720923257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282400163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":68,"alternative-id":["S104084282400163X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104420","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104420"}}